Development and validation of a 16-gene T-cell- related prognostic model in non-small cell lung cancer
We identified a 16-gene T-cell-related prognostic model for NSCLC, which stratifies patients by risk and predicts treatment response, aiding personalized therapy decisions. However, prospective validation is needed to confirm its clinical applicability. Potential limitations such as sample size and generalizability should be considered.
Authors
- Anbing Zhang (ORCID: https://orcid.org/0000-0002-2606-1640)
- Jianping Liang (ORCID: https://orcid.org/0000-0002-2733-2860)
- Jun Ma (ORCID: https://orcid.org/0000-0002-2686-5673)
- Ting Huang (ORCID: https://orcid.org/0000-0003-1041-2167)
- Xiuqiong Xia
- Xiaoli Lao
- Siqi Li (ORCID: https://orcid.org/0000-0002-1660-105X)
Institutions
- Guangdong Medical College (CN)
- Shenzhen University (CN)
- Zhongshan People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1566597
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09